Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for findings the program ...

Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental ...

Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities ...

Poster 3.31eP: Rationale and design of a safety, tolerability, and long-term efficacy study of Forazapadin (SAT-3247) in facioscapulohumeral muscular dystrophy (FSHD) Presenter: Wildon Farwell, MD, ...

An update from Satellos Bioscience ( ) is now available. On September 9, 2026, Satellos Bioscience announced that its lead drug candidate SAT-3247 has been assigned the Internatio ...

Duchenne muscular dystrophy (DMD) is a genetic disease in which muscle cells fail to produce a protein called dystrophin. Unlike some other forms of muscular dystrophy, in Duchenne there is a complete ...

Most parents wouldn’t be thrilled with the idea of their kids getting hooked up to an IV bag filled with trillions of viruses. But for Melanie Hennick, whose son, Connor, has Duchenne muscular ...

TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition. Families ...

The "Duchenne Muscular Dystrophy - Market Insight, Epidemiology, Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The Duchenne muscular dystrophy (DMD) market reached ...

Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Today, the world stands at a crossroads in genetic medicine ...